Bacterial pneumonia

Medicine

Volumn 36, Issue 6, 2008, Pages 285-290

  Loebinger, Michael R ^a   Wilson, Robert ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

antibiotics; bacteria; community acquired pneumonia; infection; pneumonia; vaccination

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAM; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; FLUCLOXACILLIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANAMNESIS; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; BRONCHIECTASIS; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG MEGADOSE; FOLLOW UP; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; MORBIDITY; MORTALITY; NURSING HOME; PATHOGENESIS; PATHOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; VACCINATION;

EID: 44149096519     PISSN: 13573039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpmed.2008.03.011     Document Type: Review

References (23)

1. British Thoracic Society guidelines for the management of community acquired pneumonia in adults. Thorax 56 suppl 4 (2001) IV1-IV64
2. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 suppl 2 (2007) S27-S72
3. Kauppinen M.T., Saikku P., Kujala P., Herva E., and Syrjala H. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 51 (1996) 185-189
4. Theerthakarai R., El Halees W., Ismail M., Solis R.A., and Khan M.A. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest 119 (2001) 181-184
5. Macfarlane J.T., and Boldy D. 2004 update of BTS pneumonia guidelines: what's new?. Thorax 59 (2004) 364-366
6. Lettinga K.D., Verbon A., Weverling G.J., et al. Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis 8 (2002) 1448-1454
7. Lim W.S., Macfarlane J.T., Boswell T.C., et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 56 (2001) 296-301
8. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336 (1997) 243-250
9. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58 (2003) 377-382
10. Arnold F.W., Ramirez J.A., McDonald L.C., and Xia E.L. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest 124 (2003) 121-124
11. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
12. Lim W.S., and Macfarlane J.T. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 18 (2001) 362-368
13. Peckham D., and Elliott M.W. Pulmonary infiltrates in the immunocompromised: diagnosis and management. Thorax 57 suppl 2 (2002) II3-II7
14. Confalonieri M., Potena A., Carbone G., Porta R.D., Tolley E.A., and Umberto M.G. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 160 (1999) 1585-1591
15. British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax 57 (2002) 192-211
16. Dunbar L.M., Wunderink R.G., Habib M.P., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 37 (2003) 752-760
17. el Moussaoui R., de Borgie C.A., van den B.P., et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 332 (2006) 1355
18. Halm E.A., Fine M.J., Kapoor W.N., Singer D.E., Marrie T.J., and Siu A.L. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 162 (2002) 1278-1284
19. Cornu C., Yzebe D., Leophonte P., Gaillat J., Boissel J.P., and Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 19 (2001) 4780-4790
20. French N. Use of pneumococcal polysaccharide vaccines: no simple answers. J Infect 46 (2003) 78-86
21. Alanee S.R., McGee L., Jackson D., et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 45 (2007) 52-54
22. Simon L., Gauvin F., Amre D.K., Saint-Louis P., and Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39 (2004) 206-217
23. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174 (2006) 84-93